Melamix TM
Texto original en francés.
Producto de salud natural autorizado en Canadá
- Otros nombres
- Melamin TM
- Titular
- ZO Skin Health Inc.
- NPN o DIN-HM
- 80038901
- Estado
- Licencia no activa
- Fecha de licencia
- 21 de enero de 2013
- Fecha de revisión
- 10 de julio de 2015
- Forma
- Crème
- Vía de administración
- Topique
- Tipo de solicitud
- Non traditionnelle
El análisis de dosis orales no se aplica sin una vía exclusivamente oral establecida.
Composición
| Ingrediente medicinal y fuente | Por unidad posológica, según la fuente |
|---|---|
| 1,4-Benzènediol Fuente : Hydroquinone | 4 % |
Ingredientes no medicinales
Glycérine, Acide glycolique, Dihydrogénophosphate d'aminopropyl, Phénoxyéthanol, Maltodextrine, Acétate de dl-alpha tocophéryle, Extrait de fleur/feuille/tige de Stachys officinalis, Stearyl Alcohol, Caprylyl Glycol, Sodium Metabisulfite, Saponins, EDTA de sodium, Lauryl sulfate de sodium, Extrait de germes de Brassica oleracea italica (Brocoli), Palmitate d'ascorbyle, Aqua, Huile de graine d'Helianthus annuus (Tournesol), Acide ascorbique, bêta-glucane, Sodium Sulphite, Chlorphenesin, Alcool cétylique
Dosis recomendadas en Canadá
| Población | Edad | Cantidad por toma | Frecuencia |
|---|---|---|---|
| Adultes | Non précisée | Non précisée | Non précisée |
Usos autorizados en Canadá
For the gradual lightening of hyperpigmented skin associated with various skin conditions such as chloasma, melasma, freckles, senile lentigines, and other skin discolourations. Skin bleaching/lightener.
Texto original en inglés.
Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.
Advertencias en Canadá
Cautions and Warnings : If you have a family history of, have or have had or are at risk of developing cancer, do not use.To be used only on the advice of a physician. Apply only to small skin surface areas. Discontinue use and consult a physician in case of skin reactions or a blue-black darkening of the skin. In case of accidental ingestion, seek medical assistance or contact a Poison Control Center immediately. Not for use on children under 12 years of age. This product contains glycolic acid, an alpha-hydroxy acid (AHA), which may increase skin's sensitivity to the sun and particularly the possibility of sunburn. Limit sun exposure and apply a sunburn protectant while using this product and for a week afterwards. Use only as directed. Do not apply over sunburn or irritated skin. A mild transient stinging or minor redness may occur in people with sensitive skin. To test for sensitivity, before treatment, apply to an area of approximately 1 cm2 of unbroken skin on the inside of the arm. If no irritation occurs within 24 hours, begin treatment for up to 12 weeks. Discontinue use in case of irritation, rash, excessive inflammatory response or if a gradual blue-black darkening of the skin (exogenous ochronosis) occurs. Minor redness is acceptable, but where there is excessive irritation, a rash or other reaction, further treatment is not advised. Severe itching or reddening may occur, in which case the product should be discontinued and the physician notified immediately. The safety of topical hydroquinone use during pregnancy or for children 12 years old or less has not been established. Note: slight darkening of the product is normal and does not affect its potency. Do not use this product if you have used it or any of its ingredients before and skin sensitivity or irritation has occurred. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product. Close patient supervision is recommended. A bitter taste and anesthetic effect may occur if applied to lips. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure may cause skin re-darkening. Treatment should be limited to relatively small areas of the body at one time.
Texto original en inglés.
Contra-Indications : Do not use this product if you are nursing, pregnant or if you intend to become pregnant within three months of use.For external use only. Do not use near eyes, mucous membranes, or on broken or irritated skin. In case of contact, rinse thoroughly with water. If irritation occurs and/or persists, contact a health care practitioner.
Texto original en inglés.
Known Adverse Reactions : Hypersensitivity (i.e. localized contact dermatitis) may occur; in such case, discontinue use and contact a heath care practitioner. Contains sodium metabisulfite, a sulfite that may cause serious allergic-type reactions including anaphylactic symptoms (e.g. hives, itching), and life threatening or less severe asthmatic episodes in certain susceptible persons.
Texto original en inglés.
Fuente
Ficha oficial de Health Canada, licencia 80038901
Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Texto original en francés.
Texto original en francés.
La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.
Lista en la revisión oficial del (registro: Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias).